Ghost Tree Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Ghost Tree Capital’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-500,000	Closed	-$8.51M	–	60
2020 Q4	$8.51M	Buy	+500,000	New	+$6.26M	1.9%	23
2016 Q1	–	Sell	-100,000	Closed	-$4.15M	–	70
2015 Q4	$4.15M	Sell	100,000 -400,000	-80%	-$13.4M	1.7%	25
2015 Q3	$7.7M	Buy	500,000 +75,000	+18%	+$1.61M	3.46%	3
2015 Q2	$10.6M	Buy	425,000 +325,000	+325%	+$7.24M	3.42%	6
2015 Q1	$2.29M	Buy	+100,000	New	+$2.52M	0.82%	51

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Ghost Tree Capital's FPRX Position: Q1 2021 in Review

Ghost Tree Capital sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 500,000 shares — an estimated $8.51M sold.

Ghost Tree Capital first reported a position in FPRX in Q1 2015 and held it in 5 quarters. The position peaked at $10.6M in Q2 2015. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

Ghost Tree Capital reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
Ghost Tree Capital sold 500,000 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $8.51M.
Ghost Tree Capital first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 5 quarters.
Ghost Tree Capital's Five Prime Therapeutics, Inc. position peaked at $10.6M in Q2 2015.
147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Ghost Tree Capital's 13F filing for Q1 2021, filed 14 May 2021.